ABSTRACT
Kingsberg et al. described results from two 24-week Phase III trials of bremelanotide for treating hypoactive sexual desire disorder (HSDD) in women. 72.72% of protocol-listed outcomes were not reported by Kingsberg et al., who provided results of 15 secondary measures which were not listed in the study protocols. None of their efficacy outcomes were reported in line with CONSORT data reporting standards and no secondary outcome had a stated rationale or cited evidence of validity. My meta-analysis of the trials’ data, based on the FDA New Drug Application, found similar results to Kingsberg et al. However, Kingsberg et al. did not report that a) adverse event-induced study discontinuation was substantially higher on bremelanotide: OR = 11.98, 95% CI = 3.74–38.37, NNH: 6 or b) participants preferred placebo, measured by the combination of both 1) completing a clinical trial and 2) electing to participate in the follow-up open-label study (OR = 0.30, 95% CI = .24-.38, NNH: 4). Bremelanotide’s modest benefits on incompletely reported post-hoc measures of questionable validity in combination with participants substantially preferring to take placebo suggest that the drug is generally not useful. Kingsberg et al.’s data reporting and measurement practices were incomplete and lacked transparency.
Acknowledgments
I have holdings in Vanguard Healthcare, a mutual fund that invests heavily in pharmaceutical firms. I thank Jaya Stenquist for her thoughtful discussion and background research regarding the medical and psychiatric conceptualizations of female sexuality. I thank Lori Brotto, Cynthia Graham, John Sakaluk, and an anonymous reviewer for their helpful comments on prior versions of this manuscript.